Vera Therapeutics (VERA) Total Current Liabilities (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Total Current Liabilities data on file, last reported at $45.1 million in Q1 2026.

• Quarterly Total Current Liabilities rose 106.22% year-over-year to $45.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.1 million (up 106.22% YoY) and the FY2025 annual result came in at $53.5 million, up 110.69% from the prior year.
• Total Current Liabilities eased to $45.1 million in Q1 2026, from $53.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $53.5 million in Q4 2025 to a low of $14.5 million in Q1 2024.
• A 5-year average of $26.9 million and a median of $24.6 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 432.08% — and 2024, when it tumbled 38.19%.
• Tracing VERA's Total Current Liabilities over 5 years: stood at $25.6 million in 2022, then declined by 12.88% to $22.3 million in 2023, then gained by 13.76% to $25.4 million in 2024, then surged by 110.69% to $53.5 million in 2025, then fell by 15.54% to $45.1 million in 2026.
• The last three Total Current Liabilities figures came in at $45.1 million (Q1 2026), $53.5 million (Q4 2025), and $41.9 million (Q3 2025), per Business Quant data.